LNA-ANTIMIR Trademark

Trademark Overview


On Wednesday, January 4, 2012, a trademark application was filed for LNA-ANTIMIR with the United States Patent and Trademark Office. The USPTO has given the LNA-ANTIMIR trademark a serial number of 79114443. The federal status of this trademark filing is IR CANCELLED - US APPLICATION ABANDONED as of Tuesday, January 4, 2022. This trademark is owned by SANTARIS PHARMA A/S. The LNA-ANTIMIR trademark is filed in the Chemical Products, Pharmaceutical Products, and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical preparations for the treatment of infectious diseases, metabolic disorders, inflammatory diseases, cardiovascular diseases, gastro-intestinal diseases, diseases of the central nervous system, autoimmune diseases, genetic disorders and malignant diseases; chemical preparations for pharmaceutical, medical and therapeutic purposes, namely, for the treatment of infectious diseases, metabolic disorders, inflammatory diseases, cardiovascular diseases, diseases of the central nervous system autoimmune diseases, genetic disorders and malignant diseases

Chemicals for use in industry and science; active chemical ingredients for use in the manufacture of pharmaceuticals or pharmaceutical development candidates for treating infectious diseases, metabolic disorders, inflammatory diseases, cardiovascular diseases, gastro-intestinal diseases, diseases of the central nervous system, autoimmune diseases, genetic disorders and malignant diseases; chemicals for use in the manufacture of medical and scientific preparations; nucleotides, nucleotide analogues and oligonucleotides for medical research and development

Scientific and technological services, namely, biopharmaceutical research as well as research and design connected thereto, namely, design and development of pharmaceutical products, biomedical and biotechnological analysis and research; development of medical and biomedical products and preparations; biochemical and molecular biological analysis; scientific, biotechnological and biomedical consultancy; in vivo and in vitro pre-clinical testing of potential pharmaceutical, medical preparations, methods and products
lna-antimir

General Information


Serial Number79114443
Word MarkLNA-ANTIMIR
Filing DateWednesday, January 4, 2012
Status402 - IR CANCELLED - US APPLICATION ABANDONED
Status DateTuesday, January 4, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment of infectious diseases, metabolic disorders, inflammatory diseases, cardiovascular diseases, gastro-intestinal diseases, diseases of the central nervous system, autoimmune diseases, genetic disorders and malignant diseases; chemical preparations for pharmaceutical, medical and therapeutic purposes, namely, for the treatment of infectious diseases, metabolic disorders, inflammatory diseases, cardiovascular diseases, diseases of the central nervous system autoimmune diseases, genetic disorders and malignant diseases
Pseudo MarkLNA-ANTIMI R
Goods and ServicesChemicals for use in industry and science; active chemical ingredients for use in the manufacture of pharmaceuticals or pharmaceutical development candidates for treating infectious diseases, metabolic disorders, inflammatory diseases, cardiovascular diseases, gastro-intestinal diseases, diseases of the central nervous system, autoimmune diseases, genetic disorders and malignant diseases; chemicals for use in the manufacture of medical and scientific preparations; nucleotides, nucleotide analogues and oligonucleotides for medical research and development
Goods and ServicesScientific and technological services, namely, biopharmaceutical research as well as research and design connected thereto, namely, design and development of pharmaceutical products, biomedical and biotechnological analysis and research; development of medical and biomedical products and preparations; biochemical and molecular biological analysis; scientific, biotechnological and biomedical consultancy; in vivo and in vitro pre-clinical testing of potential pharmaceutical, medical preparations, methods and products

Classification Information


International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status CodeH - NOT AVAILABLE
Class Status DateTuesday, January 4, 2022
Primary Code001
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeH - NOT AVAILABLE
Class Status DateTuesday, January 4, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status CodeH - NOT AVAILABLE
Class Status DateTuesday, January 4, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameSANTARIS PHARMA A/S
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressDK

Trademark Events


Event DateEvent Description
Monday, August 1, 2022NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
Sunday, July 31, 2022DEATH OF INTERNATIONAL REGISTRATION
Friday, November 7, 2014NEW REPRESENTATIVE AT IB RECEIVED
Thursday, March 13, 2014FINAL DECISION TRANSACTION PROCESSED BY IB
Monday, February 24, 2014FINAL DISPOSITION NOTICE SENT TO IB
Saturday, February 22, 2014FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Saturday, January 11, 2014NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Thursday, December 26, 2013NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, December 25, 2013NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Friday, February 22, 2013ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Friday, February 22, 2013ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Friday, August 17, 2012REFUSAL PROCESSED BY IB
Friday, July 27, 2012NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, July 27, 2012REFUSAL PROCESSED BY MPU
Friday, July 27, 2012NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, July 27, 2012APPLICATION FILING RECEIPT MAILED
Thursday, July 26, 2012NON-FINAL ACTION WRITTEN
Monday, July 23, 2012ASSIGNED TO EXAMINER
Monday, July 23, 2012NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, July 20, 2012LIMITATION FROM ORIGINAL APPLICATION ENTERED
Thursday, July 19, 2012SN ASSIGNED FOR SECT 66A APPL FROM IB